热门资讯> 正文
PharmaCyte Biotech宣布对MYMD战略投资700万美元
2024-05-21 21:16
- PharmaCyte Biotech (NASDAQ:PMCB) announced a $7 million investment in MyMD Pharmaceuticals (NASDAQ:MYMD), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions.
- PharmaCyte’s investment in externally developed technology solidifies its strategy to prudently apply its approximately $65 million (as of March 31, 2024) cash position.
- Source: Press Release
More on MyMD Pharmaceuticals, PharmaCyte Biotech, Inc., etc.
- Financial information for MyMD Pharmaceuticals
- Financial information for PharmaCyte Biotech, Inc.
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。